



ENACTING A RISK PLAN DURING COVID-19

Brian S. Schultz Environmental, Health & Safety Manager

www.tissuetech.com



Brian S. Schultz


ABOUT BRIAN

Brian S. Schultz joined TissueTech in September 2019 with over 13 years of Environmental, Health and Safety (EHS) industry experience. Brian has experience in providing safety leadership during emergency management events, developing behavior-based safety training programs for senior leadership and working with front-line employees providing guidance in achieving an incident-free worksite. Brian has a passion for safety and protecting the environment.

As a proud graduate from the University of Oklahoma with a bachelor's degree in Meteorology and a minor in Broadcast Journalism, outside of work you will find Brian cheering on his Oklahoma Sooners. He is an avid beach goer and health nut. You can find Brian enjoying his 15-year-old puppy or spending time with friends and family.

AGENDA

- About TissueTech Inc.
- Preparing for COVID-19
- Phasing into work
- Working while remaining SAFE
- Current conditions






ABOUT TISSUETECH INC.



MIAMI-DADE COUNTY



OUR VISION AND MISSION



We empower healthcare professionals to deliver optimal patient healing outcomes, setting the standards that define regenerative medicine.

We do this by living our **MISSION**:







as the PATIENT-FOCUSED PIONEER



FOSTERING TRUST



as the EVIDENCE-BASED LEADER



PROVIDING HEALTH ECONOMIC VALUE

OUR VALUES






Conduct all interactions with utmost level of INTEGRITY AND ETHICS



Deliver the HIGHEST
QUALITY and most COSTEFFECTIVE therapies for
the benefit of patients



Foster innovation through PROVEN SCIENCE and STRONG CLINICAL EVIDENCE



Provide a HIGHPERFORMANCE CULTURE
where people are
accountable, respectful
and enjoy what they do



PREPARING FOR COVID-19

EMERGENCY OPERATIONS COMMITTEE



- Senior leadership representing all business functions first met on March 9th, 2020.
- Developed an Emergency Operations Committee (EOC) team.
 - Review hospital bed data, localized trends, government shutdown guidance, etc.
 - Make decisions for our business.

| Attendance t. | | <u>EMERG</u> | ENCY | OPER | ATIO | 10 | | Meeting Date | e/Time | | 1 |
|--|--------------------------|--------------|-----------|-----------|---------------|------------|----------|--------------|---------|--------------|-----|
| Attendance pt. Member Name | Coronavirus (CO | VID-19) | Adviso | ory #/Tim | e | | | Name | | | 1 |
| Member M | 1 | | | | | | Backup | Name | | | - 1 |
| RESIDENT PERATIONS R R ACQUITIES T T ENS* COC QUALITY *1: EOC Director Current Environmental Conditions and Commuting Hazards: County Active Cases Miami Dade Broward Palm Beach Florida (State) San Diego Remains open Florida (State) San Diego Doral D | Member | Name | | | | | | | | | |
| PERATIONS R | | | | | | | | | | | |
| ACIUTIES T T EHS* CCO QUALITY *1: EOC Director Current Environmental Conditions and Commuting Hazards: County Active Cases Miami Dade Broward Palm Beach Florida (State) San Diego Business Status: Location Doral Doral Landing HQ Dopen No impact Location Open No impact Landing HQ Dopen | PERATIONS | | | | \rightarrow | | | | | | - 1 |
| ### County County | | | | | - | | | | | | - 1 |
| TEHS* CFO CCO QUALITY *1: EOC Director Current Environmental Conditions and Commuting Hazards: County Active Cases Deaths Schools Comment Active Cases Deaths Remains open Remain | ACILITIES | | | | - | | | | | | - 1 |
| EHS* CFO CCO QUALITY *1: EOC Director Current Environmental Conditions and Commuting Hazards: County Active Cases Deaths Schools Comment Florida (State) San Diego Business Status: Location Doral Doral Emails Open – No impact Kendall Landing HQ Open – No impact Some Diego Open – No impact Ope | | | | | _ | | | | | | - 1 |
| *1: EOC Director Current Environmental Conditions and Commuting Hazards: County Active Cases Deaths Deaths Remains open | | | | | | | _ | | | | _ |
| *1: EOC Director Current Environmental Conditions and Commuting Hazards: County Active Cases Deaths Board Remains open Florida (State) San Diego Business Status: Comment Location Doral | | | | | | | + | | | | |
| *1: EOC Director Current Environmental Conditions and Commuting Hazards: County Active Cases Deaths Pamains open Remains open San Diego Business Status: Comment Location Doral Do | | | | | | | | | | | |
| *I: EOC Director Current Environmental Conditions and Commuting Hazards: County Active Cases Deaths Remains open Rema | QUALITY | | | | | | | | | | _ |
| County Active Cases Deaths Graph | •1 · EOC Director | | | | ting H | azards: | | | Schools | Comment | |
| County | - dront | nental Con | ditions a | nd Comm | luting | | Deaths | | | | |
| Remains open Rema | Current Environ | Activ | e Cases | | | | | | / % | | |
| Miami Dade | County | | T | | | | | | 1 - | Remains open | |
| Miami Dade Broward Palm Beach Florida (State) San Diego Business Status: Location Doral End Open – No impact Kendall Landing HQ Dore No impact Sopen – No | | | 1 1 | | | | | | | Remains open | |
| Niami Dade | | | | | | | | | | Remains open | |
| Remains open | Miami Dade | | | | - | | | | | Remains open | |
| Palm Beach | Broward | | | | + | | | | | Remains open | |
| San Diego Business Status: Comment | Palm Beach | | | | +- | | | | | | |
| Business Status: Location | Florida (State) | | | | | | | | | | |
| Business Status: | San Diego | | | | | | Con | ment | ~ | | |
| Doral | Business Stat | us: | | | | | | | | | |
| Doral | Location | 7 | | | | | | | | | |
| Doral □ <td></td> <td>se</td> <td>ber</td> <td>1</td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> | | se | ber | 1 | | | | | | | |
| Doral | | | | Open - | No imp | act | | | | | |
| Kendall Open – No impact Landing HQ Open – No impact Open – No impact | Doral | | - | Ocen- | No imp | act | | | | | |
| Landing HQ | Kendall Qpen – No impact | | | | | | | | | | |
| San Diego | Landing HQ | | | | | | | | | | |
| Discussion Points/Decision Made/Action Items are marked With the Discussion Points/Decision Points | Landing Lab | 岩 | | Open - | – No im | pace | and with | an "+": | | | |
| Discussion Points/Decision (1999) | San Diego | 1-1- | rision N | lade/Acti | on Item | is are mar | keu witi | | | | |
| | Discussion | n Points/De | CISION | | | | | | | | |
| | | | | | | | | | | | |
| | | | | | | | | | | | |
| | | | | | | | | | | | |
| | 1 | | | | | | | | | | |
| | | | | | | | | | | | |
| | | | | | | | | | | | |

RETURN TO WORK STRATEGY



- Conducted a thorough job hazard assessment to review workplace controls (i.e. engineering controls, administrative controls).
 - Reviewed each worksite to identify site specific challenges (i.e. social distancing, high touch points, etc.).
 - Identified what could happen if safeguards are not put in place.
 - Identified preventive measures to reduce the potential of COVID-19 exposure.
- Formally communicated the job hazard assessment to all employees for consistent messaging. Required a training record to demonstrate awareness / completion.

| | | | Document No. | FORM-0380 | | | |
|-------------------------------|-----------|--|---|-------------------------------|--|--|--|
| | | FORM | Effective Date | 03/10/2020 | | | |
| ~~ | | | | 01 | | | |
| TISSUETECH | 10 | OB HAZARD ANALYSIS FORM | Revision | | | | |
| Plonena Bluck | | | | | | | |
| ii -ard Ana | alysis | Hazards or Potential for Mishap (Physical, chemical, fire, falls, noise, heat, ergonomics, etc.) | (Include P | PE & ITaliiii. | | | |
| Sequence of Ste Activities | | noise, nead, or a | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| Additional Cons | ideration | ns: | | | | | |
| | | | | | | | |
| Addition | | | | | | | |
| Addition | | | | | | | |
| Addition | | | | | | | |
| | | | | | | | |
| Work Instruct | tions: | | | | | | |
| Work Instruct | iions: | | ve read the JHA a HA to your supervis | nd understand the or and EHS. | | | |
| Work Instruct | iions: | ment, you acknowledge that you ha Please report any concerns of the Jh | ve read the JHA al HA to your supervis | nd understand the or and EHS. | | | |
| Work Instruct | iions: | ment, you acknowledge that you ha Please report any concerns of the Jh | ve read the JHA al HA to your supervis | | | | |
| Work Instruct | ement: | | ve read the JHA al HA to your supervis | | | | |

RETURN TO WORK STRATEGY





Opportunities for Improvement

- Workstations were not spread out proportionally.
- Breakrooms, conference rooms, meeting areas posed a high risk of potentially close contact interactions.
- Supply chain limitations on personal protective equipment and hand sanitizer.
- High touch areas identified.

TEMPORARY SHUT DOWN



- On March 20, 2020, the EOC determined a temporary shutdown was appropriate to protect employees which included our entire manufacturing operation.
- Employees were asked to work remotely as a preventive measure to protect each other's health and safety. Controlling the spread was our TOP Priority.
- Transitioned from face to face into a virtual meetings while keeping deadlines on projects.






PHASING INTO WORK

DIVIDING UP TO SLOW THE SPREAD



- Created 4 groups within which each employee was categorized.
 - Groups focused on personal safety and social distancing.
- Worked with the Information and Technology (IT) group to extend our support of remote work (i.e. increased licenses to virtual meetings, conference call capacity changes, supported workstation moves, etc.).





GROUP 1

Consisted of essential employees who could only perform the job functions onsite.

These employees play a pivotal role within our organization. They are the bloodline of our products and our success.





GROUPS 2 & 3

Consisted of employees who could perform their job function onsite or offsite and have virtual capabilities.

Used workflow patterns within teams and workstation locations as determining factors of group assignment.





GROUP 4

Consisted of employees who were at an increased risk of contracting COVID-19 based on CDC Guidance.

If the employee felt they fall in group 4 based on CDC, they were asked to bring a letter from a medical professional to HR. The letter would not identify the underlying condition, but only state the employee is of increased risk of contracting COVID-19.



PHASED IN APPROACH



















Work Day

Monday

Tuesday


Wednesday

Thursday

Friday

ADDITIONAL CHALLENGES





- Recognized mental health concerns from stress.
- Parents of children in need during school closures.
- Food & basic need shortages at grocery stores.
- Outside guests visiting the office locations.



WORKING WHILE REMAINING SAFE



- Increased the frequency of cleaning in common areas.
- Staggered work shifts for our essential workers (Group 1).
- Minimized interactions with Group 1 employees.
- Conducted over 30 office/workspace moves to provide adequate social distancing.

| Date: | | - | | |
|---|---------|------|-----|-----|
| ltem | 10:30am | 12pm | 2pm | 5pm |
| Wipe down coffee machines / vending machines | | | | |
| Conference room table and chair backs/arm rests | | | | |
| Door handles (both sides) | | | | |
| Bathroom counter tops | | | | |
| Breakroom counter tops and refrigerator | | | | |
| Main entrance door | | | | |
| Secondary entrance door | | | | |
| Shipping and receiving door | | | | |
| Water machine buttons | | | | |
| | | | | |
| | | | | |

SIGNAGE FOUND IN COMMON GATHERING PLACES







SIGNAGE FOUND IN COMMON GATHERING PLACES





















Plexiglass Barriers with Custom Mounting Brackets








THOUGHTFUL REMINDERS OF SOCIAL DISTANCING






6-foot COVID-19 Pool Noodle



Walkway Guidance (Social Distancing)

HANDLING POSITIVE CASES & CONTACT TRACING





- Employees were asked to communicate if they were in close contact with someone who tested positive for COVID-19.
- Employees were asked to leave the office space immediately.
- Human Resources contacts the employee to understand the nature of contact with the positive COVID-19 case.
- Employee contact tracing begins.
- Employees go in quarantine until test results from the original contact employee comes back as nondetect.

IMPACT TO OUR FIELD EMPLOYEES





- Utilized virtual meetings to meet with doctors and support the clinical needs.
- Provided frequent communication to all field employees of TissueTech's proactive COVID-19 response measures.
- Provided a COVID-19 care package filled with PPE.
- Conducted multiple webinars with doctors to provide educations material for emergency and elective procedures.



BIO-TISSUE & AMNIOX NATIONAL PRO ED WEBINARS







NATIONAL PRO ED WEBINARS BIO-TISSUE



| Date | Speaker(s) | Webinar Title | | | | |
|----------------|---|--|--|--|--|--|
| April 14, 2020 | Zarmeena Vendal, MD | PROKERA for Ocular Surface Disease in Glaucoma Patients | | | | |
| April 15, 2020 | Neel Desai, MD | A New Surgical Approach to Pterygium Surgery for Better Outcomes & Shorter OR Time | | | | |
| April 16, 2020 | Paul Karpecki, OD | Using PROKERA to Effectively Treat Ocular Surface Damage | | | | |
| April 21, 2020 | Mark Miner, MD | The Latest in Treating Corneal Ulcers & How to Incorporate PROKERA | | | | |
| April 23, 2020 | John Rumpakis, OD | Best Practices for Coding & Billing with PROKERA | | | | |
| April 28, 2020 | Neel Desai, MD | Treating EBMD & OSD Prior to Cataract Surgery | | | | |
| April 30, 2020 | Scheffer Tseng, MD, PhD | The Latest Clinical & Scientific Research Developments of CAM Therapy | | | | |
| May 5, 2020 | Atul Jain, MD | PROKERA for Ocular Surface Disease in AMD Retina Patients | | | | |
| May 6, 2020 | Pedram Hamrah, MD & Thomas John, MD | Corneal Nerve Regeneration Journal Club | | | | |
| May 12, 2020 | Ravi Patel, MD | Using AmnioGraft for the Treatment of Mechanical Dry Eye (Conjunctivochalasis) | | | | |
| May 14, 2020 | Seema Nanda, OD | PROKERA: A Corneal "Rebirth" | | | | |
| May 21, 2020 | Doug Devries, OD & John Rumpakis, OD, MBA | PROKERA Clinical & Coding Overview | | | | |
| May 27, 2020 | Neel Desai, MD; Paul Karpecki, OD; Ranjan Malhotra, MD; Samuel Lee, MD | Overcoming the Obstacles of Telehealth in Eye Care: Lessons Learned & What's Here to Stay | | | | |
| June 16, 2020 | Neel Desai, MD & Preeya Gupta, MD | Optimizing the Ocular Surface Prior to Cataract Surgery in the New Age of Telehealth | | | | |
| July 1, 2020 | Doug Devries, OD & Curtis Manning, MD | Implementing Co-Management of Mechanical Dry Eye Patients within an OD/MD Practice | | | | |
| July 22, 2020 | Zeba Syed, MD | Cryopreserved Amniotic and Umbilical Cord Tissue: Promoting Regeneration in Severe Ocular Surface Diseases | | | | |

NATIONAL PRO ED WEBINARS AMNIOX



| Date | Speaker(s) | Webinar Title |
|-----------------|---|---|
| April 14, 2020 | Mark Gould, MD | Platform Science of Cryopreserved Umbilical Cord and its Application in Foot & Ankle Trauma and Tendon Repair |
| April 15, 2020 | Alan Block, DPM | Using NEOX in the treatment of Complex Wounds in Lower Extremities |
| April 23, 2020 | Ryan Putnam, MD | Surgical Application of Cryopreserved Umbilical Cord in Calcaneal Fracture Repairs |
| May 9, 2020 | Mark Gould, MD; Allen Raphael, DPM; Ryan Putnam, MD; Jeffrey Haupt, DPM | LIVE VIRTUAL SYMPOSIUM: Supporting Surgical Wound Healing & Functional Recovery with Cryopreserved Umbilical Allografts |
| May 20, 2020 | Timothy Wilson, MD & Ravi Munver, MD | Innovations in Regenerative Urologic Reconstruction and Radical Prostatectomy |
| May 21, 2020 | Albert Dunn, DO | Incorporating UC/AM Transplantation in Complex Orthopedic Sports Medicine |
| June 16, 2020 | William Marston, MD | Using Cryopreserved Umbilical Cord Allograft to Treat Wagner Grade 3-4 DFUs |
| June 23, 2020 | Javan Bass, DPM | Managing Wound Healing in Lower Limb Amputation Using Cryopreserved Umbilical Cord |
| July 16, 2020 | Greg Berlet MD; Kent Ellington, MD; Selene Parekh, MD | Innovations in Foot & Ankle Recon: Cryopreserved Umbilical Cord Allograft as an Adjunct to Manage Expedited Recovery |
| August 19, 2020 | Robert Anderson, MD | Using Placental Tissue to Improve Surgical Outcomes in Sport Foot and Ankle Injuries |



CURRENT CONDITIONS

TIMELINE OF EVENTS







March 9, 2020

COVID-19 Emergency Operations Committee (EOC) formed.

Began capturing resources to prepare for worst case scenario.

March 20, 2020

Manufacturing paused all operations.

EOC announced a work from home order.

Essential activities (i.e. atmospheric monitoring for product safety) are still being performed on location.

March 23, 2020

Worksite modifications to improve facility conditions for COVID-19.

May 11, 2020

Phased in approach began.

Rotational schedule began with safety measures in place and proper personal protective equipment provided.

Office moves for additional spacing occurred.

October 5, 2020


Modification to Phased in approach.

Flexible Schedule (3 days/week)

Groups 1-3 began to work together on the same day (limited).

CURRENT OPERATIONS





- Continue the phased in approach.
- Social distancing in our facilities is still working.
- Monitoring current trends and CDC guideline changes.
- Continually reminding employees to encourage team members and support each other.
- Keeping employees engaged in our COVID-19 response.
- EOC still meets on a regular basis.

ACCOMPLISHMENTS & MILESTONES





From The Editor | August 11, 2020

How TissueTech Managed Growth, Virtual Trials, And Survived COVID-19



Since its inception in 1997, TissueTech has been a pioneer in the clinical application of human birth tissues. The company's products have been used in more than 500,000 human transplants across multiple indications, under the regulatory classification of human cell and tissue products (HCT/Ps).

"Our mission is to develop and commercialize regenerative therapies derived from human birth tissue for patients with serious unmet clinical needs," says Amy Tseng, CEO and co-founder of the company. "We want to be the industry leader in this segment while also making our trials patient centric. These two factors have been a key driver in our transition from a leader in the tissue space to an emerging biotech company."



Tseng co-founded the company along with her husband, Scheffer C.G. Tseng, MD, PhD. He has spent 30 years researching and identifying the active biological components of human birth tissues to determine their therapeutic use. The company has also worked closely with U.S. Food and Drug Administration (FDA) to understand their views. Tseng credits her company's early work as a factor that influenced its ability to rapidly advance Investigational New Drug programs. Build Internal Capabilities

so TissueTech announced the initiation of the first of two Phase a clinical trials of Cryopreserved Umbilical Cord TTAXO1 to

Accomplishments

No transmitted cases of COVID-19 at TissueTech!

Milestones

- Clinical Leader feature article on TissueTech.
 - "How TissueTech Managed Growth, Virtual Trials, And Survived COVID-19" by Ed Miseta, Chief Editor.

THANK YOU!

bschultz@tissuetechinc.com



